Previous Close | 51.82 |
Open | 52.08 |
Bid | 0.00 x 800 |
Ask | 54.87 x 800 |
Day's Range | 50.39 - 54.74 |
52 Week Range | 29.10 - 54.74 |
Volume | |
Avg. Volume | 1,386,803 |
Market Cap | 4.518B |
Beta (5Y Monthly) | 1.18 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.11 |
Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 62.75 |
Cytokinetics Inc (NASDAQ: CYTK) reported Q2 sales of $88.96 million compared to $2.84 million a year ago, primarily due to the recognition of $87 million deferred revenue for sales royalties of mavacamten as a result of the extinguishment of royalty obligations. The analysts estimated sales of $3.63 million. The company reported an EPS loss of $(0.23), down from $(0.86) a year ago. In June, the company received an FDA notice on plans to convene an Advisory Committee meeting to review the omecamt
Cytokinetics (CYTK) delivered earnings and revenue surprises of 77.88% and 2,483.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Advisory Committee Meeting to Review NDA for Omecamtiv Mecarbil Scheduled for December 13, 2022; PDUFA Target Action Date Set for February 28, 2023 Company Revises 2022 Financial Guidance; Reduces Projected Spending for 2022 SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the second quarter of 2022. Net loss for the second quarter was $19.8 million, or $0.23 per share, compared to net loss for the second quar